Triple-Negative Breast Carcinoma (TNBC) is a subtype of breast cancer, devoid of ER, PR and Her2 expression, with minimal response to anti-HER2 drugs, shorter disease-free and overall survival (1-4) and a unique gene expression, with varied expressions of two basal-like proteins BL1 & BL2, an immunomodulatory, mesenchymal, mesenchymal stem cell-like, and luminal androgen receptor, each being associated with a different outcome (5, 6). Here, ESR1 is linked to triple-negative breast carcinoma.